Literature DB >> 20402388

Challenges of treating asthma in people who smoke.

Mark Spears1, Euan Cameron, Rekha Chaudhuri, Neil C Thomson.   

Abstract

Cigarette smoking is common in asthma and is associated with poor symptom control and a reduced therapeutic response to inhaled and oral corticosteroids as compared with nonsmokers with asthma. This review examines the range of adverse health effects of smoking in asthma, the inflammatory mechanisms that may influence the efficacy of current drugs and discusses potential future therapeutic directions.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20402388     DOI： 10.1586/eci.09.85

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


  6 in total

1.  Results from a community-based program evaluating the effect of changing smoking status on asthma symptom control.

Authors:  Teresa To; Corinne Daly; Rachel Feldman; Susan McLimont
Journal:  BMC Public Health       Date:  2012-04-20       Impact factor: 3.295

Review 2.  Emerging therapies for severe asthma.

Authors:  Neil C Thomson; Rekha Chaudhuri; Mark Spears
Journal:  BMC Med       Date:  2011-09-06       Impact factor: 8.775

3.  Omalizumab: clinical use for the management of asthma.

Authors:  Neil C Thomson; Rekha Chaudhuri
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2012-06-12

4.  Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians.

Authors:  David Price; Brooke Harrow; Mark Small; James Pike; Victoria Higgins
Journal:  World Allergy Organ J       Date:  2015-09-10       Impact factor: 4.084

Review 5.  The management of asthmatic smokers.

Authors:  José Miguel Chatkin; Cynthia Rocha Dullius
Journal:  Asthma Res Pract       Date:  2016-06-20

Review 6.  Asthma risk factors.

Authors:  Elina Toskala; David W Kennedy
Journal:  Int Forum Allergy Rhinol       Date:  2015-09       Impact factor: 3.858
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.